Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
03:31pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
04:01pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decl
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
08:30am, Monday, 17'th Oct 2022
HERCULES, Calif.
Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year?
08:00am, Wednesday, 12'th Oct 2022
Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
12:29pm, Tuesday, 11'th Oct 2022 Benzinga
Reuters
US-China Chip War: KLA Relaxes Chip Supply To China
U.S. chipmaker KLA Corp's (NASDAQ: KLAC) legal department emailed China informing that it shall stop sales and service to "advanced f
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
12:04pm, Tuesday, 11'th Oct 2022
A rumored matchup between Bio-Rad Laboratories and Qiagen is unlikely, an analyst said Tuesday as BIO stock fell for a second straight day. The post Why Bio-Rad Laboratories' Rumored $10 Billion Qiage
Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
12:56am, Tuesday, 11'th Oct 2022 MarketWatch
The talks have been going on for a while, but any agreement isn’t likely for another few weeks or more — and there may not be one.
Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market
08:56pm, Monday, 10'th Oct 2022
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.
Bio-Rad Laboratories in Talks to Combine With Qiagen
02:03pm, Monday, 10'th Oct 2022
Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
01:57pm, Monday, 10'th Oct 2022 Zacks Investment Research
Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
05:26pm, Friday, 07'th Oct 2022 Zacks Investment Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
05:08pm, Friday, 07'th Oct 2022 Zacks Investment Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
04:44pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
02:00pm, Monday, 03'rd Oct 2022 Zacks Investment Research
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
The S&P 500 sank 5% in a very bad week for stocks. These 20 lost as much as 24%.
10:12am, Monday, 19'th Sep 2022 MarketWatch
A profit warning from FedEx, an expensive acquisition for Adobe and fear of the Federal Reserve all weighed on the stock market.
